{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-124182","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.640574+00:00","generated_at":"2026-06-07T16:10:18.523871+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Hepion CEO resigns, interim CEO named; restructuring plan to cut costs 60%","bullets":["Dr. Robert Foster resigns as CEO and director for personal reasons, effective immediately.","John Cavan (CFO) appointed interim CEO; Dr. Peter Wijngaard also resigns from board.","Board approves strategic restructuring to reduce operating costs by ~60%, with one-time charge of $400-$800K in Q4 2023.","Company to explore strategic alternatives including M&A, licensing, or sale; 131 patients in Phase 2b NASH trial.","Cash runway extended into Q2 2025; will add trial patients only if fully funded or strategic deal."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-124182","json":"https://secwatch.observer/filing/0001104659-23-124182.json","markdown":"https://secwatch.observer/filing/0001104659-23-124182.md","text":"https://secwatch.observer/filing/0001104659-23-124182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923124182/0001104659-23-124182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923124182/tm2332355d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:10:18.523871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d15398d86","claim":"John Cavan was appointed as interim Chief Executive Officer at Hepion Pharmaceuticals, Inc..","evidence_excerpt":"the Board of Directors appointed John Cavan, the Company’s Chief Financial Officer, as interim Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923124182/0001104659-23-124182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"89aba6aa23","claim":"Dr. Robert Foster resigned as Chief Executive Officer at Hepion Pharmaceuticals, Inc..","evidence_excerpt":"Dr. Robert Foster, the Company's CEO, resigned from the Company as CEO for personal reasons, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923124182/0001104659-23-124182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e39c95364e","claim":"Dr. Peter Wijngaard resigned as Director at Hepion Pharmaceuticals, Inc..","evidence_excerpt":"Dr. Peter Wijngaard resigned from the Board of Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923124182/0001104659-23-124182-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}